{"disease":{"id":"carcinoid","name":"carcinoid"},"drugs":{"marketed":[{"drug_id":"lanreotide","indication_name":"Carcinoid Syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Somatuline Depot","generic_name":"LANREOTIDE","company_name":"Ipsen Pharma","drug_phase":"marketed","molecular_target":"Somatostatin receptor type 2","drug_class":"Somatostatin Analog","quality_score":10,"revenue":"1200","mechanism":"Somatuline Depot works by mimicking the natural hormone somatostatin to block the production of excess growth hormone."},{"drug_id":"octreotide","indication_name":"Carcinoid syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sandostatin","generic_name":"OCTREOTIDE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Somatostatin receptor type 2","drug_class":"Somatostatin Analog","quality_score":75,"revenue":"305","mechanism":"Sandostatin works by mimicking the natural hormone somatostatin to inhibit the release of various hormones and growth factors."},{"drug_id":"telotristat-ethyl","indication_name":"Carcinoid Syndrome Diarrhea","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TELOTRISTAT ETHYL","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07317726","title":"Recent Trends in Stage Migration of Gastrointestnial Carcinoid Tumors Over Two Decades: a Retrospective SEER-based Analysis 2000-2022","phase":"","overall_status":"COMPLETED","enrollment_count":93481,"lead_sponsor_name":"Suez Canal University","has_results":false},{"nct_id":"NCT07291752","title":"The Risk of Second Primary Gastrointestinal Malignancies Following Primary Gastrointestinal Carcinoid Tumors: a SEER Based Study 2000-2022","phase":"","overall_status":"COMPLETED","enrollment_count":93481,"lead_sponsor_name":"Suez Canal University","has_results":false},{"nct_id":"NCT07317713","title":"A Two-decade Mortality Risk Analysis of Gastrointestinal Carcinoid Neoplasms: an Updated SEER-based Study 2000-2022","phase":"","overall_status":"COMPLETED","enrollment_count":93481,"lead_sponsor_name":"Suez Canal University","has_results":false},{"nct_id":"NCT02628067","title":"Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1609,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT00646022","title":"Natural History of Familial Carcinoid Tumor","phase":"","overall_status":"RECRUITING","enrollment_count":1600,"lead_sponsor_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","has_results":false},{"nct_id":"NCT03583528","title":"DOTATOC PET/CT for Imaging NET Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":800,"lead_sponsor_name":"British Columbia Cancer Agency","has_results":false},{"nct_id":"NCT03498040","title":"Development and Progression of Carcinoid Heart Disease in a Cohort of Adult Patients With Neuroendocrine Tumors","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":670,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT07389512","title":"Pharmaceutical Management in Targeted Radioligand Therapy","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT04907643","title":"Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes","phase":"NA","overall_status":"RECRUITING","enrollment_count":360,"lead_sponsor_name":"Cedars-Sinai Medical Center","has_results":false},{"nct_id":"NCT02177773","title":"GA-68 DOTA-TOC of Somatostatin Positive Malignancies","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":300,"lead_sponsor_name":"University of California, San Francisco","has_results":true},{"nct_id":"NCT02754297","title":"Personalized PRRT of Neuroendocrine Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":275,"lead_sponsor_name":"CHU de Quebec-Universite Laval","has_results":false},{"nct_id":"NCT01010126","title":"Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":252,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01578239","title":"A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":231,"lead_sponsor_name":"Advanced Accelerator Applications","has_results":true},{"nct_id":"NCT01619865","title":"Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":223,"lead_sponsor_name":"Sue O'Dorisio","has_results":true},{"nct_id":"NCT03223428","title":"Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO","phase":"","overall_status":"COMPLETED","enrollment_count":223,"lead_sponsor_name":"TerSera Therapeutics LLC","has_results":true},{"nct_id":"NCT05969860","title":"At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05756608","title":"Fibrosis in Chronic and Delayed Myocardial Infarction","phase":"","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"University of Edinburgh","has_results":false},{"nct_id":"NCT04028479","title":"The Registry of Oncology Outcomes Associated With Testing and Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":167,"lead_sponsor_name":"Taproot Health","has_results":false},{"nct_id":"NCT05176665","title":"EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":152,"lead_sponsor_name":"Shanghai EpimAb Biotherapeutics Co., Ltd.","has_results":false},{"nct_id":"NCT05670574","title":"Surgery With Extended (D3) Mesenterectomy for Small Bowel Tumors","phase":"NA","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"Sykehuset i Vestfold HF","has_results":false},{"nct_id":"NCT03110978","title":"Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":140,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01677910","title":"TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":135,"lead_sponsor_name":"Lexicon Pharmaceuticals","has_results":true},{"nct_id":"NCT02026063","title":"Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":124,"lead_sponsor_name":"Lexicon Pharmaceuticals","has_results":true},{"nct_id":"NCT07450287","title":"CardioNETPOL National Registry of Carcinoid Heart Disease","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"National Institute of Cardiology, Warsaw, Poland","has_results":false},{"nct_id":"NCT02826928","title":"Diagnostic Performances of Urine and Plasma 5-hydroxyindolacetic Acid (5HIAA) Values in Patients With Small-intestine Neuroendocrine Tumors","phase":"NA","overall_status":"COMPLETED","enrollment_count":116,"lead_sponsor_name":"CHU de Reims","has_results":false},{"nct_id":"NCT06472388","title":"Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"AC Camargo Cancer Center","has_results":false},{"nct_id":"NCT04735198","title":"Prophylactic Cholecystectomy in Midgut NETs Patients Who Require Primary Tumor Surgery.","phase":"NA","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Hospital Universitari de Bellvitge","has_results":false},{"nct_id":"NCT02063659","title":"Telotristat Etiprate for Carcinoid Syndrome Therapy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":76,"lead_sponsor_name":"Lexicon Pharmaceuticals","has_results":true},{"nct_id":"NCT00688623","title":"RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":73,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT04993261","title":"An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors","phase":"EARLY_PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":71,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04017104","title":"Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging","phase":"","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"British Columbia Cancer Agency","has_results":false},{"nct_id":"NCT03622333","title":"Clinic, Pathologic and Genetic Characterization of Patients With Familial Carcinoid Tumors (Study From the GTE, Groupe d'étude Des Tumeurs Endocrines)","phase":"NA","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"CHU de Reims","has_results":false},{"nct_id":"NCT02795858","title":"A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":43,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":true},{"nct_id":"NCT06757920","title":"\"Bronchoscopic Argon Plasma Coagulation for Managing Endobronchial Carcinoid Lesions","phase":"NA","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Alexandria University","has_results":false},{"nct_id":"NCT05361668","title":"Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Crinetics Pharmaceuticals Inc.","has_results":true},{"nct_id":"NCT03950609","title":"Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":36,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02399215","title":"Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT01165658","title":"Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":30,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01435122","title":"A Study of Axitinib in Advanced Carcinoid Tumors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":true},{"nct_id":"NCT01253161","title":"Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":true},{"nct_id":"NCT05448157","title":"68Ga-DOTATOC Radio-Guided Surgery With β-Probe in GEP-NET","phase":"","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"European Institute of Oncology","has_results":false},{"nct_id":"NCT02575300","title":"Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":true},{"nct_id":"NCT05557708","title":"A Safety Study of 212Pb-Pentixather Radioligand Therapy","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Yusuf Menda","has_results":false},{"nct_id":"NCT04197310","title":"Cabozantinib and Nivolumab for Carcinoid Tumors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":true},{"nct_id":"NCT03879694","title":"Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT01104415","title":"Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Lexicon Pharmaceuticals","has_results":true},{"nct_id":"NCT01327612","title":"Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT04073017","title":"Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency","phase":"NA","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"Vanderbilt-Ingram Cancer Center","has_results":false},{"nct_id":"NCT03722511","title":"Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Lowell Anthony, MD","has_results":false},{"nct_id":"NCT04140409","title":"Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}